Myeloablative conditioning regimens for AML allografts: 30 years later (Q35574536)

8 August 2017

title

Myeloablative conditioning regimens for AML allografts: 30 years later (English)

1 reference

8 August 2017

Gupta V

1

1 reference

8 August 2017

Lazarus HM

series ordinal

2

1 reference

8 August 2017

Keating A

series ordinal

3

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

Bone Marrow Transplantation

8 August 2017

published in

1 reference

8 August 2017

volume

32

1 reference

8 August 2017

issue

10

1 reference

8 August 2017

page(s)

969-978

1 reference

Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Is there a best transplant conditioning regimen for acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Solid cancers after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first compl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Bone marrow transplantation in the busulfan-treated rat. II. Effect of cyclophosphamide and antithymic serum on the presensitized state

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Risk factors in interstitial pneumonitis following allogenic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704285

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704285

1 reference

8 August 2017

1 reference